MED at a glance
MEDIFAST INC (MED, SEC CIK 910329) filed its latest 10-K annual report on February 17, 2026, a 10-Q quarterly report on October 26, 2026, an 8-K current report on October 26, 2026 and Form 4 insider filings as recently as November 20, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 31, 2025 (FY2025), MEDIFAST INC (MED) reported revenue of $385.8 million (down 36.0% from FY2024) and a net loss of $18.7 million. Diluted EPS was -$1.70.
- As of September 30, 2026, 20 institutional investment managers tracked by SignalX reported holding MEDIFAST INC (MED) shares worth $39.9 million in 13F-HR filings.
- The most recent insider open-market purchase reported on Form 4 was by Kiai Parsa on November 19, 2026 of 2,450 shares at $12.05 per share.
- In the last 90 days, MED insiders reported 11 open-market purchases ($1.8M) and 2 open-market sales ($226K) on Form 4, a net purchase of $1.6M.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $385.8M
- −36.0% vs prior year
- Insiders · 90 days
- 11 buys · 2 sells
- Net +$1.6M
- 13F holders
- 20 funds
- $39.9M · −2 vs prior quarter
- Latest 8-K
- Oct 26, 2026
- Item 2.02
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Sep 30, 2026
Risk Factors
- No material changes to 2025 Form 10-K risk factors disclosed
- Carried-forward risks include regulatory, operational, competitive, market, and financial exposures disclosed in the 2025 Form 10-K
Management Discussion & Analysis
- Revenue $72.0M, down 19.4% YoY from $89.4M, driven by active earning coaches declining to 10,200 from 19,500
- Gross margin 69.5% vs 69.5% YoY; operating margin (26.9%) vs (4.6%), with net loss $17.5M vs $2.3M
- Average revenue per active earning coach $7,064, up 54.1% from $4,585, the strongest reported performance metric
- Cash, cash equivalents and investments $172.5M vs $167.3M at December 31, 2025; operating cash flow $5.3M vs $12.1M
- Active earning coaches expected to decline through year-end 2026; GLP-1 adoption, inflation and tariffs remain headwinds
AI summary of the MED 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 2.02: Results of Operations and Financial Condition
- Q3 FY2026 earnings release issued October 26, 2026
- Reporting period ended September 30, 2026
Item EX-99.1: Item EX-99.1
- Q3 revenue $72.0M, down 19.4% YoY, as active earning coaches fell 47.7% to 10,200
- Coach productivity improved 54.1% to $7,064, but management expects coach declines through year-end 2026
Item EX-99.1: Item EX-99.1
- Q2 revenue $76.4M, down 27.6% year over year, reflecting continued demand pressure and rapid GLP-1 adoption
- Active earning coaches fell 48.7% to 11,700, while revenue per coach rose 41.0% to $6,529
Item 2.02: Results of Operations and Financial Condition
- Q2 FY2026 earnings released August 3, 2026, covering the quarter ended June 30, 2026
- Detailed financial results and management commentary contained in Exhibit 99.1
Item 7.01: Regulation FD Disclosure
- OPTAVIA rebranded as Trilivy, repositioning Medifast’s wholly owned lifestyle brand around comprehensive metabolic health
- Strategic shift broadens brand positioning beyond traditional weight management toward an integrated metabolic-health offering
AI summaries of MED 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for MED
Don't miss the next MED filing
- Alerts as it files. A push when MED files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut MED, by share count.
- Ask anything. An AI agent that reads every MED filing and answers with sources.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| Kiai Parsa | Buy | Nov 19, 2026 | 2,450 | $12.05 |
| Kiai Parsa | Buy | Nov 19, 2026 | 82,700 | $12.05 |
| Kiai Parsa | Buy | Nov 18, 2026 | 8,630 | $12.16 |
| Kiai Parsa | Buy | Nov 18, 2026 | 256 | $12.16 |
| Kiai Parsa | Buy | Nov 4, 2026 | 661 | $13.03 |
| Kiai Parsa | Buy | Oct 28, 2026 | 158 | $12.24 |
| Kiai Parsa | Buy | Oct 28, 2026 | 5,399 | $12.24 |
| Chard Daniel R | Sell | Sep 29, 2026 | 9,544 | $11.73 |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | - | $602.5M | $385.8M |
| Gross Profit | - | $444.6M | $275.2M |
| Operating Income | - | $2.9M | -$14.2M |
| Net Income | - | $2.1M | -$18.7M |
| Gross Margin | - | 73.8% | 71.3% |
| Op. Margin | - | 0.5% | -3.7% |
| Net Margin | - | 0.3% | -4.8% |
| Balance Sheet | |||
| Total Assets | $309.9M | $284.2M | $248.0M |
| Equity | $201.5M | $210.1M | $198.9M |
| ROE | - | 1.0% | -9.4% |
| Per Share | |||
| EPS | - | $0.19 | $-1.70 |
| Cash Flow | |||
| Operating CF | - | $24.5M | $6.9M |
| CapEx | - | $7.5M | $5.6M |
Source: XBRL data in MEDIFAST INC (MED)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q3 2026Aggregate MED share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q3 2026 | 20 | $39.9M |
| Q2 2026 | 22 | $39.8M |
| Q1 2026 | 21 | $45.3M |
| Q4 2025 | 22 | $52.1M |
| Q3 2025 | 22 | $78.7M |
| Q2 2025 | 25 | $77.9M |
| Q1 2025 | 21 | $56.9M |
| Q4 2024 | 19 | $63.0M |
- BlackRock+143.7K (+39%)
- Renaissance Technologies LLC+79.9K (+10%)
- Citadel Advisors LLC+31.2K (+55%)
- Two Sigma Investments+11.3K (+2%)
- Dimensional Fund Advisors+10.0K (+3%)
- AQR Capital Management−200.0K (-85%)
- Goldman Sachs Group−120.5K (-50%)
- D.E. Shaw & Co−57.7K (-63%)
- Morgan Stanley−48.2K (-16%)
- Millennium Management−30.0K (-63%)
- Prudential Financial+46.8K
- Citigroup+546
- Bank of America Corp−87.1K
- Vanguard Portfolio Management LLC−29.1K
- Invesco Ltd−13.3K
- FMR LLC (Fidelity)−2.7K
Source: 13F-HR filings on SEC EDGAR (aggregated from 172 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
MED filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
10-Q quarterly reports
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 4 | Nov 20, 2026 | - | - | - |
| 4 | Nov 6, 2026 | - | - | - |
| 4 | Oct 30, 2026 | - | - | - |
| 10-Q | Oct 26, 2026 | Sep 30, 2026 | Analysis | |
| 8-K | Oct 26, 2026 | - | Analysis | - |
| 4 | Sep 30, 2026 | - | - | - |
| 4 | Aug 28, 2026 | - | - | - |
| 4 | Aug 26, 2026 | - | - | - |
| 4 | Aug 21, 2026 | - | - | - |
| SC 13G | Aug 14, 2026 | - | - | |
| 10-Q | Aug 3, 2026 | Jun 30, 2026 | Analysis | |
| 8-K | Aug 3, 2026 | - | Analysis | - |
| 8-K | Jul 17, 2026 | - | Analysis | - |
| 8-K | Jun 1, 2026 | - | Analysis | |
| 4 | May 28, 2026 | - | - | |
| 4 | May 28, 2026 | - | - | |
| 4 | May 28, 2026 | - | - | |
| 4 | May 28, 2026 | - | - | |
| 4 | May 28, 2026 | - | - | |
| 4 | May 28, 2026 | - | - | |
| 8-K | May 26, 2026 | - | Analysis | |
| SC 13G | May 15, 2026 | - | - | |
| 4 | May 12, 2026 | - | - | |
| 8-K | May 4, 2026 | - | Analysis | - |
| 10-Q | May 4, 2026 | Mar 31, 2026 | Analysis |
Related Consumer Staples companies
- MKC · McCormick & CompanyMiscellaneous Food Preparations & Kindred Products
- UTZ · Utz Brands, Inc.Miscellaneous Food Preparations & Kindred Products
- ACI · Albertsons Companies IncRetail-Grocery Stores
- MO · AltriaCigarettes
- ANDE · Andersons, Inc.Wholesale-Farm Product Raw Materials
- BUD · Anheuser-Busch InBev SA/NVMalt Beverages
- ADM · Archer Daniels MidlandFats & Oils
- ARKO · ARKO Corp.Retail-Convenience Stores
MED SEC filings: frequently asked questions
Are MED insiders buying or selling?
In the last 90 days, MEDIFAST INC (MED) officers, directors and 10% owners reported 11 open-market purchases worth $1.8 million by 1 insider and 2 open-market sales worth $226,289 by 1 insider on Form 4, a net purchase of $1.6 million. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.
Which institutions hold MED stock?
As of September 30, 2026, the largest MEDIFAST INC (MED) holders among the 13F filers tracked by SignalX were Renaissance Technologies LLC ($9.9 million), BlackRock ($5.9 million), Two Sigma Investments ($5.7 million), Vanguard Capital Management LLC ($5.1 million), Dimensional Fund Advisors ($4.3 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What was MED's revenue in fiscal year 2025?
For the fiscal year ended December 31, 2025 (FY2025), MEDIFAST INC (MED) reported revenue of $385.8 million (down 36.0% from FY2024) and a net loss of $18.7 million. Diluted EPS was -$1.70. The figures come from the XBRL data in the 10-K.
What did MED report in its latest 8-K?
MEDIFAST INC (MED) filed an 8-K on October 26, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Q3 FY2026 earnings release issued October 26, 2026.
What are the latest MED SEC filings?
MEDIFAST INC (MED) filed its latest 10-K annual report on February 17, 2026, a 10-Q quarterly report on October 26, 2026, an 8-K current report on October 26, 2026 and a Form 4 insider filing on November 20, 2026.
What is MED's SEC CIK number?
MEDIFAST INC (MED)'s SEC Central Index Key (CIK) is 910329. EDGAR lists every MED filing under that number.
Ask anything about MED
The research agent reads MED's filings, financials, insider trades and 13F holders, then answers with sources.